Cutaneous Leishmaniasis Completed Phase 2 Trials for Sargramostim (DB00020)

Also known as: Leishmaniasis, Cutaneous / Cutaneous leishmaniasis (disorder)

IndicationStatusPhase
DBCOND0028439 (Cutaneous Leishmaniasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00973128Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisTreatment